4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
Portfolio Pulse from Benzinga Insights
Four analysts have recently provided ratings for Teva Pharmaceutical Indus (NYSE:TEVA), showing a mix of bullish and somewhat bullish perspectives. The average 12-month price target has increased to $18.75, with a high estimate of $21.00 and a low estimate of $14.00. Analysts from B of A Securities, Piper Sandler, and Barclays have raised their price targets, while JP Morgan has announced a neutral rating. Despite positive revenue growth, Teva faces challenges with profitability, debt management, and financial returns.
May 30, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teva Pharmaceutical Indus (NYSE:TEVA) has received mixed ratings from analysts, with an average price target increase to $18.75. Analysts from B of A Securities, Piper Sandler, and Barclays have raised their price targets, while JP Morgan has announced a neutral rating. Despite positive revenue growth, Teva faces challenges with profitability, debt management, and financial returns.
The increase in the average price target and the positive ratings from major analysts like B of A Securities, Piper Sandler, and Barclays suggest a short-term positive impact on TEVA's stock price. However, the company's challenges with profitability, debt management, and financial returns may temper this optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100